Author name: Lottie Wurr

Cambridge Cognition’s Global Teams Unite for Mental Health Causes! 

News Back to resource centre 24 November 2022 Cambridge Cognition unveils strategic partnership for Chinese market expansion Cambridge Cognition is pleased to announce an expansion in the Chinese market through a strategic partnership with Luca Healthcare Limited, a category leader in digital screening, treatment and management tools in China. Cambridge Cognition has signed an exclusive licencing agreement with Luca Healthcare

The next generation of treatments for Alzheimer’s Disease in clinical trials

The latest advances in the treatment of Alzheimer’s disease and how Cambridge Cognition are designing and implementing empirically validated and clinically-relevant cognitive tasks to help develop the next generation of Alzheimer’s disease treatments. 

There are presently over 140 drugs being explored as possible treatments for Alzheimer’s Disease (AD) in clinical trials. Of these, nearly 80% are intended to slow the progression of AD. Historically, cholinesterase inhibitor drugs such as galantamine, rivastigmine and donepezil have been approved for treatment of AD. These drugs have been shown to mitigate symptoms of AD, such as memory loss, however they are unable to treat the underlying neurobiological cause of the condition. As such, these drugs do not slow AD progression and are not considered a long-term solution in the battle to end the most common form of neurodegenerative disease.

Using a multidisciplinary approach to characterise the neurobiology of addiction

Insights Back to resource centre 6 October 2022 Understanding the effect of ashwagandha root extract on stress, sleep and cognition We caught up with Shefali Thanawala from Nutriventia Ltd who told us how CANTAB™ helped them to investigate the effects of Ashwagandha root extract on memory and focus in healthy, stressed adults. About Nutriventia, Ltd.Nutriventia Limited is the dietary supplements

Bi-weekly assessment process

Evaluating the utility of daily speech assessments for monitoring depression symptoms

Publications & posters Back to resource centre 11 January 2023 Evaluating the utility of daily speech assessments for monitoring depression symptoms Depression is a common mental health disorder and a major public health concern, significantly interfering with the lives of those affected. DIGITAL HEALTH recently published a paper on “Evaluating the utility of daily speech assessments for monitoring depression symptoms”

Monitoring fluctuations in psychiatric symptoms though analysis of speech

Webinars Back to resource centre 11 January 2023 Monitoring fluctuations in psychiatric symptoms though analysis of speech Several psychiatric disorders including major depression, bipolar disorder and schizophrenia are accompanied by changes in vocal patterns and use of language. These disorders are also characterized by fluctuations in symptomatology that are not well captured using standard clinical assessments. More fine grain monitoring

Speech analytics and natural language processing for automation of quality assurance in clinical trials

Webinars Back to resource centre 11 January 2023 Speech analytics and natural language processing for automation of quality assurance in clinical trials In CNS clinical trials the gold standard primary outcome measures are often clinician rated instruments. While these assessments are capable of capturing changes in disease they can easily be confounded by gaps in rater training or knowledge and

Speech biomarkers from active and passive collection of voice in Alzhiemer’s disease clinical trials

Webinars Back to resource centre 11 January 2023 Speech biomarkers from active and passive collection of voice in Alzhiemer’s disease clinical trials Changes in speech and language are hallmark characteristics of Alzheimer’s disease. While these changes are core to clinical evaluation, we have historically lacked objective tools for measuring these changes in the context of clinical trials. During this webinar,

Pictures of Ed and Yasmin

Improvements and personalisation of research and treatment in schizophrenia and psychosis-related disorders; observations from Schizophrenia International Research Society (SIRS) 2023 conference.

Insights Back to resource centre 31 May 2023 Improvements and personalisation of research and treatment in schizophrenia and psychosis-related disorders; observations from Schizophrenia International Research Society (SIRS) 2023 conference. Earlier this month we had the pleasure of attending the Schizophrenia International Research Society (SIRS) conference in Toronto, Canada. We were delighted to present our recent findings from our meta-analysis comparing

Hub Xchange Europe 2023

Events Back to resource centre Hub Xchange Europe 2023 Date and time 22 November 2023 Location Zurich, Europe About this event Meet us Sessions, presentations & posters Poster: Validating a set of Verbal-Paired-Associates word-pair lists for Repeat, Remote, Automated Testing. Saturday, July 30 (Technology and Dementia Preconference) and Tuesday, August 2 Dual tasking paradigm in clinical stages of early Alzheimer’s

CTIP 2023

Events Back to resource centre CTIP 2023 Date and time 15-16 November 2023 Location New York, USA About this event Join World BI for its 22nd edition of Clinical Trials Innovation & Outsourcing Programme to learn from the best in the drug development industry and have an opportunity to learn from their experiences. With an agenda covering the future of

Scroll to Top